Small Molecule TLR2 Inhibitors Targeting BB Loop Pocket
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective inhibitors for Toll-like Receptor 2 (TLR2) signaling, which is implicated in various inflammatory diseases, and there is no TLR2 inhibitor licensed for human use.
Innovation Solution
Identification of small molecule inhibitors, such as C29 and its derivative ortho-vanillin, using Computer-Aided Drug Design (CADD) that target the BB loop pocket of the TLR2 TIR domain to inhibit TLR2 signaling, demonstrating therapeutic potential by blocking TLR2/1 and TLR2/6 pathways in human and murine cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are designed to target the BB loop pocket of TLR2 TIR domain, then TLR2 signaling inhibition is achieved, but the complexity of drug design and development increases
Solution Approach 1:
The patent applies local quality by specifically targeting the BB loop pocket region within the TLR2 TIR domain. Instead of attempting to inhibit the entire receptor, the invention focuses drug design on this critical local region where the BB loop (containing conserved proline residues) mediates essential protein-protein interactions. This localized targeting approach achieves effective TLR2 signaling inhibition while reducing the overall complexity compared to designing against the entire receptor structure.
Solution Approach 2:
The patent employs small molecule compounds as intermediary substances that bind to the BB loop pocket and disrupt the protein-protein interactions between TLR2 and its signaling adapters (MyD88, TIRAP). These small molecules serve as mediators that translate the structural features of the BB loop pocket into specific inhibitory activity, simplifying the drug design process by focusing on small molecule-蛋白质 binding rather than complex protein-protein interaction engineering.
2Object-affected harmful factors
If TLR2 signaling is blocked to prevent cytokine storm, then tissue damage is reduced, but the ability to detect and respond to microbial pathogens is impaired
Solution Approach 1:
The patent applies partial action by selectively inhibiting only the excessive or dysregulated TLR2 signaling pathways that lead to cytokine storm and tissue damage, rather than completely blocking all TLR2 activity. The BB loop pocket-targeted inhibitors are designed to modulate signaling intensity, allowing sufficient pathogen detection and immune response while preventing the harmful overactivation that causes tissue damage. This selective partial inhibition resolves the contradiction between protecting against pathology and maintaining protective immunity.
3Ease of manufacture
If the BB loop pocket is targeted for therapeutic intervention, then novel therapeutic agents can be developed, but understanding of TIR domain interactions must be deeply established
Solution Approach 1:
The patent applies preliminary action by conducting extensive structural and functional characterization of the BB loop pocket and its role in TIR domain interactions before proceeding to therapeutic agent development. The invention first establishes the critical importance of the BB loop (particularly conserved proline residues like P681 in human TLR2) for protein-protein interactions through mutagenesis studies and structural analysis. This preliminary understanding creates a solid foundation that simplifies subsequent drug design and development, as the target site and mechanism of action are already well-defined.
Data Source
AI summary
The present invention is drawn to therapeutics and methods of inhibiting signaling by TLR2. The invention provides a method of treating an inflammatory disease or condition in a subject comprising administering to the subject a therapeutically effective amount of a compound of the invention or salt, solvate, hydrate, prodrug, metabolite, or combination thereof.